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Background
Breast cancer is the most common cancer in women worldwide. In 2012, globally the 
incidence rate and mortality rate of breast cancer was 38.9 and 13.0 per 100,000 (Ferlay 
et al. 2013). In Thailand, while the incidence rate was relatively lower (22.4 per 100,000), 
the mortality rate was slightly higher (13.8 per 100,000) (Ferlay et al. 2013). The 5-year 
prevalence was 54,269 cases in the country (Ferlay et al. 2013). Among all breast cancer 
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patients in Thailand, metastatic breast cancer accounted for 8.8  %, which tended to 
require advance and costly therapy (National Cancer Institute, Thailand 2011).
Immunohistochemistry has advanced breast cancer prognosis and treatments by 
identifying hormone receptor (HR) oestrogen receptor (ER) and/or progesterone (PR) 
and human epidermal growth factor receptor HER2 pathways (Park et al. 2012; Dedes 
et  al. 2011). Based on these receptor pathways, breast cancers are classified into four 
subtypes—luminal A (ER+ and/or PR+, HER2−, Ki-67 < 14 %), luminal B (ER+ and/
or PR+, HER2−, Ki-67  ≥  14  % or ER+ and/or PR+, HR2+), HER2-enriched (ER−, 
PR−, HER2+), and triple-negative breast cancer (TNBC) (ER−, PR−, HER2−). They 
accounted for 59.3, 12.3, 13.3, and 15.1  % of Thai women, respectively (Chuthapisith 
et  al. 2012). The use of treatments targeting the ER and HER2 in patients with early-
stage breast cancer has resulted in noticeable reductions in tumor recurrence and death, 
but resistance to these treatments often due to the activation of alternative survival path-
ways can develop and cause disease progression (Dhillon 2013). These pathways have 
been a focus for the development of new anticancer treatments.
Among those pathways, the phosphatidylinositol 3-kinases (PI3  K)/Akt/mammalian 
target of rapamycin (mTOR) pathway plays an important role in breast cancer cell pro-
liferation and cancer treatment resistance (Dhillon 2013). The inhibitor of mTOR was 
shown to restore breast cancer cells’ sensitivity to hormone. An mTOR inhibitor, everoli-
mus, has become a promising treatment for several types of tumors (Dhillon 2013). 
Everolimus was first approved only for patients with advanced renal cell carcinoma 
after failure of treatment with sunitinib or sorafenib or vascular endothelial growth fac-
tor (VEGF) targeted therapy in several countries as same as in Thailand (Dhillon 2013; 
Baselga et al. 2012; Bachelot et al. 2014). In 2012, it was approved in the US for the treat-
ment of postmenopausal women with advanced hormone receptor-positive, HER2-neg-
ative breast cancer in combination with exemestane after failure of standard treatments, 
e.g. letrozole or anastrozole (National Cancer Institute 2013). In 2013, the Breast cancer 
trials of OraL Everolimus-2 (BOLERO-2) data showed the results from final progres-
sion-free survival (PFS) analysis of everolimus used in patients with postmenopau-
sal hormone receptor-positive, HER2-negative advanced breast cancer (Yardley et  al. 
2013). The addition of everolimus to exemestane significantly prolonged median PFS, 
as compared to exemestane alone (7.8 vs 3.2 months by local investigators and 11.0 vs 
4.1  months by central assessment). After final 18-month follow-up, the percentage of 
overall survival (OS) events of everolimus plus exemestane was 25.4  % while the OS 
of exemestane alone was 32.2  %. While the most commonly reported adverse events 
of the everolimus plus exemestane included stomatitis, rash, fatigue, diarrhea, nausea, 
decreased appetite, weight loss, and cough, the most common grade 3 and 4 adverse 
events were stomatitis, fatigue, dyspnea, anemia, hyperglycemia, and gammaglutamyl-
transferase increase.
While the technology of cancer treatments has been moving forward and available 
at high costs, countries need to manage healthcare budgets efficiently. Thailand is not 
different from other countries and it needs even more resources since it also has pro-
vided universal health coverage to every citizen. Even though the data of public health 
expenditure on cancer did not exist, there were two examples showing that the country 
has focused heavily on cancer treatments and had a difficulty to ensure access to the 
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treatments. First, in 2008, Thailand needed to grant compulsory licenses for four drugs, 
which also included letrozole and docetaxel for breast cancer. Even though the public 
positively viewed this policy and its benefits, it was a contentious decision (Chalkidou 
et al. 2014). Another example was that the country has used health technology assess-
ment (HTA) as a decision making tool for allocating resources efficiently and it had 
immense influence on cancer preventions, treatments, and consequences in the coun-
try (Chalkidou et  al. 2014). One of study results, specifically related to breast cancer, 
showed that once-in-a-lifetime population-based mammographic screening for women 
aged either 40−49 or 50−59  years did not have a good value in Thailand (Chalkidou 
et  al. 2014). Historically, while Thai government and pharmaceutical industry had 
debated between treatment benefits and costs of cancer treatments, patients were rarely 
involved. As taxpayers, patients should be able to share their decisions. More attention 
should be given to patients’ preferences for treatment options, especially new and costly 
treatments. Also, if the government decided not to cover those innovative cancer treat-
ments, patients would assume very high cost burden. The objective of this study was 
therefore to understand how patients’ preferences for characteristics of postmenopau-
sal hormone receptor-positive, HER2-negative advanced breast cancer treatments after 
failure of treatment with letrozole or anastrozole and to estimate their willingness-to-
pay (WTP) by using a discrete choice experiment (DCE). Specifically, exemestane plus 
everolimus was used as a case study.
Results
Patients’ characteristics
A total of 155 breast cancer patients were invited to participate in this study. However, 
only 146 breast cancer patients were included for data analyses. The rest had wrong 
answers for the validity testing choice set. Table 1 shows patients’ characteristics. The 
overall study patients’ average age was 53.2  years old. More than 65  % of them were 
married. The majority of patients had only primary school degree. Most of them either 
owned business or worked in agriculture. Their average monthly income was US$355.2. 
Almost 80 % of them were under the universal health coverage provided by Thai govern-
ment and more than a half perceived that they had good health status, as compared to 
others at the same age. In average, they were diagnosed with breast cancer about 3 years. 
Almost 50 % of them were having hormonal therapy.
Patients’ preferences
The results of the multinomial logit model are presented in Table 2. All patients seemed 
to understand the choice tasks well. Approximately 42 % of all observations chose nei-
ther treatment alternative, while 58 % chose the either first or second alternatives in the 
choice sets. All estimated coefficients had expected signs and were statistically signifi-
cant in every model. The positive signs of the PFS parameter indicated that the patients 
preferred postmenopausal hormone receptor-positive, HER2-negative advanced breast 
cancer treatments with higher PFS. The negative signs of the anemia, pneumonitis, and 
cost parameters reflected that they preferred lower side effects and paying less money 
for the treatments. The coefficient strength of each attribute can be interpreted as its 
preference weight on patients’ utility when other attributes are assumed constant. 
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According to the coefficient strengths on the same scales of the anemia and pneumonitis 
risks, patients weighted on pneumonitis risk higher than on anemia risk of treatments, 
as indicated by the higher coefficient value (−0.29 VS −0.07).
Table 3 shows the WTP for individual attributes of postmenopausal hormone recep-
tor-positive, HER2-negative advanced breast cancer treatments after failure of treatment 
with letrozole or anastrozole. The patients’ preferences for both treatment effectiveness 
Table 1 Patients’ characteristics (N = 146)
Variables
Age (years, mean ± SD) 53.2 ± 10.2
Marital status [N (%)]
 Married 96 (65.8 %)
 Single/widowed/divorced/separated 50 (34.2 %)
Educational level [N (%)]
 Primary school 97 (66.4 %)
 Secondary school/high school/diploma 40 (27.4 %)
 College/university or higher 9 (6.2 %)
Occupation [N (%)]
 Civil servant 3 (2.1 %)
 Private firm 32 (21.9 %)
 Own business/agriculture 84 (57.5 %)
 No occupation 27 (18.5 %)
 Monthly income (US$, mean ± SD) 355.2 ± 2253.7
Health insurance [N (%)]
 Universal coverage 113 (77.4 %)
 Civil servant medical benefit scheme 13 (8.9 %)
 Others 20 (13.7 %)
Perceived current health status [N (%)]
 Poor 4 (2.7 %)
 Fair 55 (37.7 %)
 Good 77 (52.7 %)
 Very good 10 (6.8 %)
 Average years of breast cancer diagnosed (years, mean ± SD) 3.0 ± 3.1
Current breast cancer treatment [N (%)]
 Surgery 1 (0.7 %)
 Chemotherapy 18 (12.3 %)
 Hormonal therapy 68 (46.6 %)
 No treatment at the time being 47 (32.2 %)
 Do not know 11 (8.2 %)
Table 2 Estimated parameters of multinomial logit model
Log‑likelihood = −445.21, Akaike information criterion = 1.03, Pseudo‑R2  = 0.53
Attribute β-coefficient Standard error p value
Progression free survival 0.16074 0.01788 0.0000
Anemia −0.07331 0.03306 0.0266
Pneumonitis −0.29558 0.05250 0.0000
Cost per month −0.32169 × 10−4 0.16383 × 10−5 0.0000
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and adverse events were put in WTP space to make easier for comparison. Marginal 
WTP for each attribute was calculated to reflect how much respondents were willing 
to pay for a unit change of each attribute. The results showed that patients were willing 
to pay for $151.6 for every 1 month of PFS. On the other hand, they were willing to pay 
US$69.8 and US$278.3 for every one person in 100 persons to avoid anemia and pneu-
monia or pneumonitis risks from getting the treatments. Then, we obtained the attribute 
levels of both exemestane and everolimus plus exemestane from literature (Baselga et al. 
2012; Bachelot et al. 2014; National Cancer Institute 2013; Yardley et al. 2013) to calcu-
late the WTP and found that the patients in this study were WTP for exemestane and 
exemestane plus everolimus US$551.8 and US$414.2 per month, respectively.
Discussions
To our best knowledge, this was one of very few studies to elicit breast cancer patients’ 
preferences on their treatments using DCE. Recently, there have been emerging breast 
cancer treatments with some certain risks, especially adverse events. The results of this 
study could help clinicians choose the treatments, based on patients’ preferences of both 
clinical outcomes and economic burden.
This study intended to examine patients’ preferences for attributes of postmenopausal 
hormone receptor-positive, HER2-negative advanced breast cancer treatments after fail-
ure of treatment with letrozole or anastrozole and to estimate their WTP for the treat-
ments. Interestingly, when patients learned about the benefits and risks of the treatment 
options that they had—aromatase inhibitor vs aromatase inhibitor plus mTOR inhibi-
tor—for this type of breast cancer after failure of standard treatments, they tended to 
agree what attributes were important to them. We could conclude within interviewing 
only six patients. Among various benefits, patients focused more on PFS than on clinical 
benefit rate and on overall survival (compared to placebo). These results were consistent 
with medical literature, which considered PFS as the primary outcome for these treat-
ments. Interestingly, among several kinds of adverse events, patients prioritized anemia 
and pneumonitis, which were two most common grade 3 or 4 adverse events from aro-
matase inhibitor plus mTOR inhibitor (Dhillon 2013). A reason could be that when they 
imagined they already suffered so much from having advanced breast cancer and they 
probably did not want any additional disease or symptom that could worsen their health. 
Also, among the adverse events they learned, anemia and pneumonitis would possibly 
sound more severe than others, e.g. stomatitis, hyperglycemia, etc.
The study results suggested that patients had different preferences for the attributes 
of postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer 
treatments after failure of treatment with letrozole or anastrozole. They were willing to 
trade among these attributes when they needed to choose the treatments. The results 
Table 3 Patients’ willingness-to-pay per  month for  one level change of  each attribute 
(US$)
Progression free survival Anemia Pneumonitis
Average willingness-to-pay 151.6 −69.8 −278.3
95 % confidence interval 121.1–182.2 (−131.6)–(−8.2) (−374.8)–(−183.9)
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were intuitive that patients preferred higher treatment efficacy (PFS), lower adverse 
events (anemia and pneumonia or pneumonitis), and lower cost. Based on the same unit 
of measurement in the DCE, apparently patients weighed more on pneumonitis than on 
anemia. One of the reasons could be that they could have heard about or had experience 
or knew someone who had pneumonitis in the past, while anemia was generally rare and 
probably harder for the patients to perceive its consequences. On the other hand, we 
could not directly compare the importance between PFS and the adverse event due to 
their different units of measurement. However, from the ratios of their estimated param-
eters, we found that the maximum levels of anemia and pneumonitis, which patients 
were willing to accept in order to increase one month of PFS, were approximately 2 and 
0.5 %, respectively. In other words, patients could accept higher risk for anemia to trade 
for PFS. Our results were inconsistent with the results from an only previous DCE study 
on breast cancer patients’ preference for prophylactic granulocyte colony-stimulating 
factors (Johnson et al. 2014). Even though they might not be a good comparison due to 
various differences, e.g. populations, it was worth noting that the patients in that study 
weighed treatment effects on blood cells (neutropenia) more than on infection while 
our patients cared treatment effects on inflammation (pneumonitis) than on blood cells 
(anemia). An explanation could be that patients might have different preferences on 
treatment and prophylaxis. For prophylaxis, patients might concern more on neutrope-
nia because it could be a major disruption for their main treatment. On the other hand, 
for treatment, patients might consider that it was their main treatment and they should 
focus more on the adverse event that they have been familiar with.
The results indicated that while patients would like to have longer PFS, they had 
more concern on pneumonitis, which they might have from using the exemestane plus 
everolimus instead of exemestane alone. Even though the patients in this study had rela-
tively low monthly incomes, they were willing to pay about a half of all their average 
monthly income to trade for a month of PFS. Unfortunately, the small sample size in this 
study did not allow us to examine the association between income and WTP. Since the 
patients’ WTP for not having both anemia and pneumonitis were high, these amounts 
finally made them willing to pay monthly for exemestane plus everolimus lower than for 
exemestane alone. Interestingly, while the WTP for exemestane alone calculated from 
this study was almost four times higher than its cost (US$140.2), the WTP for exemes-
tane plus everolimus was extremely lower than its cost (US$4712.1) in Thailand. These 
costs were obtained and estimated from the (Ministry of Public Health 2013). Recently 
the estimated monthly costs for exemestane and exemestane plus everolimus from the 
same source declined to US$102.1 and US$2874.3, respectively. Ones could argue that 
WTP may not be a good estimation for market price. However, as a simple cost-benefit 
analysis, the interpretation of the results should be that the patients valued the bene-
fits for exemestane more than its cost, but they valued the benefits for exemestane plus 
everolimus much less than its cost. In other words, they realized net costs of exemes-
tane plus everolimus, which meant it was not worth their value of money in case they 
had advanced breast cancer treatments after failure of standard treatments. One of the 
reasons that the patients might perceive that everolimus cost them more than its addi-
tional benefits to exemestane could be that the additional PFS from adding everolimus 
was only approximately 7  months, which were relatively short, as compared to other 
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additional risks that patients could have during those months. It was worth mentioning 
here that the majority of these patients were under universal health coverage scheme 
sponsored by Thai government. It could be a reason that their WTP were low.
This study suffered from various limitations. First, even though DCE used in this study 
is a state-of-the-art stated preference method, ones may always argue that it does not 
reveal or reflect true preference or value since all decisions are not really made. How-
ever, this study already tried to minimize validity threats as many as possible, e.g. provid-
ing an opt-out alternative in each choice set, which resembled real-life choices. Second, 
all choice sets comprised only limited number of treatment attributes. There were other 
attributes that could also affect patients’ preferences. Further research should examine 
more attributes, which might provide better understandings of patients’ preferences and 
their WTP. However, the patient interviews would reassure that this limitation should be 
negligible. Third, since it was not possible to include only patients, who had postmeno-
pausal hormone receptor-positive, HER2-negative advanced breast cancer treatments 
after failure of treatment with letrozole or anastrozole, patients in this study could be 
at any stage of breast cancer. They might not be good representatives for this specific 
type and stage of breast cancer. However, as stated in the methods, we described the 
disease condition to ensure that they could imagine well while they were making deci-
sions. Finally, this study examined preferences among patients from only one hospital in 
southern Thailand, the results could not be generalized to patients in other settings since 
they might have different socioeconomic characteristics, especially income and educa-
tion levels, which could affect patients’ preferences and WTP.
In conclusion, this study revealed that patients weighted importance on PFS, anemia, 
and pneumonitis, when they needed to choose an aromatase inhibitor plus mTOR inhib-
itor for advanced breast cancer treatments after failure of standard treatments. Specifi-
cally, they valued net benefits for exemestane, but not for exemestane plus everolimus. 
Also, they were willing to pay more for exemestane alone than for exemestane plus 
everolimus.
Patients and methods
DCE has been used to measure the preferences of respondents for various treatment 
alternatives from well-designed choice sets in the healthcare field. This study followed 
a user’s guide for DCE published by Lancsar and Louviere (Lancsar and Louviere 2008). 
In general, DCE describes various choice sets of a treatment by its attributes, e.g. effi-
cacy, side effects, and costs. Each choice set contains various hypothetical alternatives 
with different attributes and levels, randomly combined by a rigorous method of DCE 
study design. Respondents are asked to choose one alternative that they prefer from 
each choice set. Finally, statistical analysis based on Random Utility Theory is used to 
determine the influences of attributes on respondent preference.
Attributes and levels
We reviewed the clinical literature of treatments for patients with postmenopausal hor-
mone receptor-positive, HER2-negative advanced breast cancer after failure of treatment 
with letrozole or anastrozole to develop a list of attributes for this study (Baselga et al. 
2012; Bachelot et al. 2014; National Cancer Institute 2013; Yardley et al. 2013). Primarily, 
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there were three attribute groups, including benefits [i.e (PFS), objective response rate, 
and clinical benefit rate], risks (i.e. stomatitis, anemia, hyperglycemia, fatigue, dyspnea, 
pneumonitis, rash, diarrhea), and costs. We used these attributes as a guide to conduct 
in-depth interviews with convenient sampled patients with breast cancer. These patients 
were asked about not only what attributes were important for them but also appropriate 
terms describing these attributes, assuming that they were in advanced state and stand-
ard treatments they had received fail. The interview data were transcribed verbatim after 
each interview. The data were saturated after interviewing six patients. Finally, we identi-
fied four attributes—PFS, anemia, pneumonitis, and monthly treatment cost—from only 
those attributes that were important for patients, as a result of the interview (Table 4). 
Level ranges were obtained from the same literature (Baselga et al. 2012; Bachelot et al. 
2014; National Cancer Institute 2013; Yardley et al. 2013).
Discrete choice experiment questionnaire design
From all possible combinations of selected attributes and levels (3 × 3 × 3 × 3), it was 
not feasible to present them to an individual patient. An orthogonal and level balance 
design was used to randomly draw a subset of all combinations by using Ngene® soft-
ware (version 1.1.1). In this study, 36 choice sets were generated and divided into six 
blocks. A self-administered questionnaire was developed in Thai language. Each ques-
tionnaire contained six choice sets from each block. Therefore, we had six different 
questionnaires. Each choice set consisted of two alternatives describing hypothetical 
treatments and an opt-out alternative. Figure  1 shows an example of the choice sets. 
Another choice set was added to every questionnaire for a validity check. The validity 
Table 4 Attributes and  levels of  treatments for  patients with  postmenopausal hormone 
receptor-positive, HER2-negative advanced breast cancer after  failure of  treatment 
with letrozole or anastrozole
a The exchange rate was approximately 33 Baht per US$1(Bank of Thailand 2014)
Attributes Levels
Progression free survival (PFS) 2, 8, 14 months
Anemia 0, 3, 6 %
Pneumonitis 0, 2, 4 %
Monthly cost 0, US$3030.3, US$6060.6a
Treatment A Treatment B
Progression free survival 14 months 8 months
Neither treatment 
A nor treatment B
Anemia 0 in 100 0 in 100




Please mark an “X” in the 
box you choose
Treatment A Treatment B Neither treatment 
A nor treatment B
Fig. 1 Choice set example
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check choice set contained a dominant alternative (highest efficacy, lowest side effect, 
and no cost), which must be chosen by patients who understood the questions. Ques-
tions on patients’ characteristics and experiences related to breast cancer treatments 
were included in the questionnaire. Three faculty members at Department of Pharmacy 
Administration, Faculty of Pharmaceutical Sciences, Prince of Songkla University were 
asked to check the content validity of the questionnaire before it was piloted with con-
veniently selected 10 breast cancer patients. No major problem was found.
Data collection
This study conveniently sampled breast cancer patients, who visited the outpatient sur-
gery department of a tertiary care hospital during May to September 2013 and aged 
18 years old or above. Since the number of patients, who had postmenopausal hormone 
receptor-positive, HER2-negative advanced breast cancer treatments after failure of 
treatment with letrozole or anastrozole, were small, it was not possible to select only 
them in the study. Breast cancer patients at any stage were included. However, they 
must experience surgery, radiotherapy, chemotherapy, hormonal therapy, or other can-
cer treatments, and had been in the follow-up period for at least 3 months in order to 
ensure that they had some experiences with cancer treatments. Since the choice sets 
used in this study were unlabeled choices, there was no sample size calculation formula 
(de Bekker-Grob et al. 2010). This study followed the suggestion from Rose and Bliemer 
for continually collecting data until all criteria were found statistically significant (Rose 
and Bliemer 2013). The ethics committee of the hospital, where patients were recruited, 
approved the study proposal. We explained all study details to patients. If they agreed to 
participate to the study, they needed to sign an informed consent.
Before we interviewed the patients by using the designed questionnaires, we briefly 
described and ensured that they understood about advanced breast cancer, its treat-
ments, and side effects. We asked patients to imagine if patient were in the situation 
that had already had the standard treatments for advanced breast cancer and the treat-
ments failed, then they were asked to choose two treatment alternatives and an opt-out 
alternative in each choice set. An example of a completed choice set was provided. Each 
respondent received only one questionnaire, which contained a total of seven choice 
sets.
Data analyses
Based on Random Utility Theory, patients’ responses for each choice set were observed 
and analyzed in DCE (Lancsar and Louviere 2008). The following utility, that a patient i 
assigned to an alternative j, Uij, was estimated: 
where β0 is the constant reflecting patients’ preference for having treatment relative to 
no treatment, β1, β2, β3 are the coefficients or the mean attribute weights of PFS, ane-
mia, pneumonitis, and cost, respectively, εij is error term. Multinomial logit model by 
using Nlogit® version 4 was used to estimate the utility model. The value of each coeffi-
cient indicated the relative importance of each attribute, while the sign of the coefficient 
Uij = β0 + β1PFSj + β2Anemiaj + β3Pneumonitis+ β4Costj + εij
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reflected whether the attribute had a positive or a negative effect on utility or preference, 
as compared with the base level. The level of statistical significance was set at 0.05.
Marginal WTP of the attributes were calculated by taking the ratio of the mean attrib-
ute coefficient to the mean coefficient of cost attribute. Each of them represented how 
much one was willing to pay for a 1-unit change in the attribute. Krinsky and Robb 
method was used to estimate 95 % confidence intervals of WTPs of the attributes (Krin-
sky and Robb 1986). Finally, we calculated WTP for both exemestane and exemestane 
plus everolimus by multiplying the marginal WTP for each particular treatment’s attrib-
ute and its level changes, which were obtained from literature (Baselga et al. 2012; Bach-
elot et al. 2014; National Cancer Institute 2013; Yardley et al. 2013).
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